18:10 , Mar 9, 2018 |  BC Week In Review  |  Company News

Pfizer ends PDC deal with CytomX

CytomX Therapeutics Inc. (NASDAQ:CTMX) disclosed in its 4Q17 earnings that it received notification that Pfizer Inc. (NYSE:PFE) plans to terminate a 2013 deal to develop and commercialize up to four Probody drug conjugate candidates using...
19:47 , Oct 13, 2017 |  BC Week In Review  |  Company News

Cellectar and Pierre Fabre extend PDC deal

Cellectar Biosciences Inc. (NASDAQ:CLRB) and Pierre Fabre Group (Castres, France) extended a 2015 deal to develop phospholipid drug conjugates (PDC) to treat cancer. The companies said the extension will cover combining Pierre Fabre's cytotoxic payloads...
19:07 , Jul 3, 2017 |  BC Week In Review  |  Clinical News

CytomX begins Phase I/II of CX-2009 in solid tumors

CytomX Therapeutics Inc. (NASDAQ:CTMX) began the open-label, U.S. Phase I/II PROCLAIM-CX-2009 trial to evaluate CD166 PDC (CX-2009) in about 150 patients with metastatic or locally advanced unresectable solid tumors. The trial will recruit patients with...
17:16 , Dec 9, 2016 |  BC Week In Review  |  Financial News

PDC*line completes venture financing

PDC*line raised €4 million ($4.3 million) in a series A round from Meusinvest, Spinventure, Luxembourgeoise and angel investors. The round comprises €2.6 million ($2.8 million) in capital and €1.4 million ($1.5 million) in debt. PDC*line Pharma,...
08:00 , Nov 12, 2015 |  BC Innovations  |  Product R&D

Probodies, anticancer

Lauren Martz, Senior Writer  How successful checkpoint inhibitors and chimeric antigen receptor (CAR) T cells will be at revolutionizing oncology hangs largely on whether it will be possible to curb their on-target but off-tissue toxicities. CytomX...
07:00 , Mar 13, 2014 |  BC Innovations  |  Distillery Therapeutics

Indication: Other

Indication Target/marker/pathway Summary Licensing status Publication and contact information Other Adjuvant Toll-like receptor 9 (TLR9) In vitro, mouse and primate studies suggest a CpG DNA nanoparticle wrapped...
07:00 , Aug 1, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Cancer Phosducin-like 3 (PDCL3); VEGF receptor 2 (KDR/Flk-1; VEGFR-2) Cell culture studies...
07:00 , Jul 18, 2013 |  BC Innovations  |  Distillery Therapeutics

Indication: Cancer

This week in therapeutics Indication Target/marker/pathway Summary Licensing status Publication and contact information Cancer Breast cancer Toll-like receptor 7 (TLR7) Mouse studies suggest stimulating TLR7 on...
08:00 , Jan 21, 2013 |  BC Week In Review  |  Clinical News

PDC31: Phase I data

A Phase I trial in healthy women with primary dysmenorrhea showed that PDC31 dose-dependently relieved pain and reduced intrauterine pressure. PDC31 was well tolerated with no dose-limiting toxicities (DLTs) reported. PDC said it is in...
07:00 , Apr 30, 2012 |  BC Week In Review  |  Clinical News

Theralase preclinical data

In a mouse model of colorectal cancer, intratumoral injection of Theralase's lead PDC followed by activation with the company's super-pulsed laser targeting technology completely eliminated tumors after 24 hours. Additionally, treated mice were cancer free...